biologic

Humalog

insulin lispro

Loss of exclusivityMay 2027projected — 12-year biologic exclusivity estimate
CompanyEli Lilly and Company

Drug detail

Brand nameHumalog
Active ingredientinsulin lispro
Strength600UNITS/3ML (200UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMay 2015
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Humalog patent cliff — loss of exclusivity May 2027 | CliffBio